74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Beam Therapeutics Inc
Open
SectorHealthcare
24.37 -1.14
Overview
Share price change
24h
Min
24.27
Max
25.07
Income | 357M 244M |
|---|---|
Sales | 104M 114M |
Profit margin | 214.091 |
Employees | 511 |
EBITDA | 368M 261M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +96.19% upside |
Next Earnings | 4 May 2026 |
|---|
Market Cap | -644M 2.2B |
|---|---|
Previous open | 25.51 |
Previous close | 24.37 |
News Sentiment
By Acuity
56%
44%
290 / 349 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Beam Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Beam Therapeutics Inc Forecast
Price Target
By TipRanks
96.19% upside
12 Months Forecast
Average 48.38 USD 96.19%
High 80 USD
Low 24.18 USD
Based on 12 Wall Street analysts offering 12 month price targets forBeam Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
290 / 349 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Live chat